<DOC>
	<DOC>NCT00259103</DOC>
	<brief_summary>The purpose of this study is to assess the safety and efficacy of rhRlx for cervical ripening, when compared to a placebo.</brief_summary>
	<brief_title>Recombinant Human Relaxin (rhRlx) in Pregnant Women Scheduled for Induction of Labor</brief_title>
	<detailed_description>A multicenter, randomized, double-blind, placebo-controlled, dose escalation study of healthy female subjects at â‰¥ 40 weeks gestation and who are scheduled for induction. A dose-escalation portion of the study is followed by a randomized, double-blind, placebo-controlled portion of the study. The endpoints include cervical ripening, as well as progression to labor and delivery.</detailed_description>
	<mesh_term>Methocarbamol</mesh_term>
	<criteria>Age between 18 and 40 years Normal pregnancy At least 40 weeks of gestation Otherwise healthy Anemia or hypertension Presence of chronic disease Endometriosis Known fetal anomaly Substance abuse History of cancer</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>relaxin</keyword>
	<keyword>pregnancy</keyword>
	<keyword>cervical ripening</keyword>
	<keyword>normal pregnancy at least at 40 weeks of gestation</keyword>
</DOC>